Xenon Pharmaceuticals Articles
US FDA fast-track for Sanofi Pasteur's KB001A; orphan status for Teva/Xenon's XEN402; second BD Simplist product approved
23 April 2013
Bristol-Myers Squibb signs up with another partner for daclatasvir, Merck & Co; latter expands deal with Xenon
23 April 2013
Xenon in $646 million deal with Roche unit
10 January 2012
Showing 1-4 of 4 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
